The global market for orchids, a sector valued in the hundreds of millions of dollars, is characterized by intense competition and a secretive drive to develop the next groundbreaking floral variety. This pursuit of novelty means that the laboratory has become as crucial as the traditional greenhouse in the race to create new orchid types. Centuries of human intervention through selective breeding and propagation have, according to leading Dutch orchid breeding firm Floricultura, rendered the genetic background of many commercial orchids a "disaster." This genetic legacy makes it exceptionally difficult to predict the traits of a new plant breed.
To overcome these challenges, Floricultura and its competitors are developing genetic markers for specific characteristics such as color, shape, disease resistance, and flowering longevity. These markers allow breeders to accelerate the selective breeding process. Instead of waiting up to three years for a newly bred plant to flower, breeders can now employ genetic screening techniques on very young plants. This enables them to identify and discard specimens that do not meet their requirements early in the development cycle.
Wart van Zonneveld, Floricultura's research and development manager, explains the process: "If a few thousand cross breeds [come] from the lab, we can screen them based on the marker and just select the ones that have the marker that you search for." He clarifies that these markers serve as indicators for desired or undesired traits, depending on what is easier to detect. These so-called "novel breeding techniques" are proprietary trade secrets, with each company investing heavily to develop its unique genetic markers and processes, which are essential for creating distinct varieties.
Paul Arens, an ornamental plant breeding researcher at Wageningen University in the Netherlands, notes that while the foundation of breeding remains the same – crossing two plants based on their characteristics – modern breeders are employing advanced research methods. "The foundation is still what we are doing for 100 years already. You take two plants, you look at their characteristics, and you make a cross. But [the breeders] have white lab coats, [and] they're doing all kinds of research with markers, with genomics, on plant health," Arens observes.
Genetics also play a vital role in protecting the intellectual property of newly developed orchid varieties. In Europe, this is managed through breeders' rights, while the United States utilizes patents. Companies seek exclusive rights to commercialize their creations to prevent others from replicating and selling them. Arens highlights that to qualify for breeders' rights or patents, a new variety must be distinct, stable, and uniform compared to existing market offerings. While these protections are granted based on physical descriptions, DNA analysis is instrumental in establishing distinctiveness by comparing new plants with similar existing products, akin to forensic science.
Floricultura operates on a business-to-business model, supplying new varieties to cultivators who then grow the plants at scale, rather than selling directly to the public or garden centers. The company boasts over 180 varieties in its current catalog, with several hundred more in various stages of development, driven by a constant demand for novelty. Stefan Kuiper, Floricultura's breeding manager, emphasizes the continuous nature of this work: "You can't stop, because it takes so long to develop new varieties. You have to go on, [or] you will be behind the rest."
Following genetic screening and initial selection, promising young plants undergo a development period of approximately three years. This phase involves cultivation first in laboratory settings and then in greenhouses. However, this is just one stage in a much longer development process. Arens describes breeding as "the art of throwing away," referring to the discarding of less successful plants, but also the art of multiplying the successful ones. The subsequent generation of plants are not siblings but exact clones of the selected individuals.
Floricultura pioneered the use of meristems for cloning, a technique that utilizes the plant's growth cells. "In the beginning, everybody had the seedlings, so the crossing and then the seed pods give plants, but we at Floricultura introduced meristems," Stefan Kuiper explains. While the specifics of these genetic research techniques are trade secrets, the cloned seedlings are cultivated over several years to reach another selection point.
The cultivation of orchids is an intensive process requiring consistent heat, light, water, and nutrients over extended periods. While advanced genetic and other techniques can expedite certain stages, the fundamental process of allowing plants to grow and confirming their characteristics—such as flower shape, size, color, stem count, and disease resistance—remains time-consuming. After this extensive evaluation, plants may be transported internationally, for instance, by airfreight to India or by lorry to Poland, before returning to Floricultura's extensive greenhouse facilities in Heemskerk, North Holland, which span over seven hectares for both development and production.
Resource management is a key focus. Rainwater is collected from greenhouse roofs and, in response to changing weather patterns, the company is implementing water and nutrient recycling systems for secondary use. A significant investment in sustainability is Floricultura's geothermal well, which draws water from 3 kilometers below the surface at a temperature of 102°C. This well generates substantial energy, prompting explorations into sharing this resource with the local council for district heating projects.
Technological innovation has automated many aspects of orchid cultivation. In the expansive greenhouses, automated systems move trays of plants on rollers, ensuring they progress sequentially through different cultivation stages. However, one critical task at Floricultura remains exclusively human: the final decision on which varieties, after approximately nine years of development, will be included in the company's catalog. Despite a plant meeting all genetic criteria and exhibiting desirable traits, the ultimate judgment of its commercial appeal—its beauty—is made by human experts like Stefan Kuiper and his colleagues.
"Breeding is a little bit [like] gambling," Kuiper admits, underscoring that this human element of aesthetic judgment is, for now, indispensable in the highly competitive and secretive world of orchid breeding. The industry continues to balance scientific advancement with the art of horticultural selection to bring new, desirable varieties to market.
